News
TipRanks on MSN
Needham upgrades Amicus to Buy on reduced regulatory risk
Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target The FDA’s decision to no longer require a panel meeting for Travere’s ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results